What the Trump administration's move to reclassify marijuana means for investors
- Posted on April 23, 2026
- By CNBC
- 0 Views
- 1 min read
In brief
The Trump administration's decision to reclassify FDA-approved marijuana from Schedule I to Schedule III marks a significant shift in federal drug policy. This regulatory change could reshape the pharmaceutical and cannabis investment landscape, potentially opening new opportunities for institutional investors and pharmaceutical companies while establishing stricter controls through the Controlled Substances Act framework.
What the Trump administration's move to reclassify marijuana means for investors
The Department of Justice said it will immediately move FDA-approved marijuana from Schedule I to Schedule III under the Controlled Substances Act.
